normal human complement standard (Quidel)
Structured Review

Normal Human Complement Standard, supplied by Quidel, used in various techniques. Bioz Stars score: 96/100, based on 184 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/normal+human+complement+standard/Human+Complement+Standard/pmc07468294-273-17-21
Average 96 stars, based on 184 article reviews
Images
1) Product Images from "Reg4 and complement factor D prevent the overgrowth of E. coli in the mouse gut"
Article Title: Reg4 and complement factor D prevent the overgrowth of E. coli in the mouse gut
Journal: Communications Biology
doi: 10.1038/s42003-020-01219-2
Figure Legend Snippet: a Map of complement-mediated bactericidal activity. b The proportion of gut bacteria after 16s rRNA analyses of colon contents in normal CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CFDKO) mice (pooled samples from six mice). Also see Fig. . c The proportion of gut bacteria after 16s rRNA analyses in CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CFDKO) mice after 2% DSS. Also see Fig. . d The proportion of E. coli (Escherichia-Shigella) in CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CFDKO) mice after 2% DSS ( n = 5). Also see Fig. S3C. e Flow cytometry of feces bacteria after staining using anti-LPS antibodies in CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CDKO) mice after 2% DSS. f QPCR of colonic content (upper) and colonic tissues (lower) in CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CFDKO) mice after 2% DSS ( n = 6). g FISH of E. coli in the gut tissues of CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CFDKO) mice after 2% DSS. One representative from six mice. Scale bar, 40 μM; Scale bar in bottom panel, 5 μM. Two side student’s t test in e and f ; * P < 0.05; ** P < 0.01; *** P < 0.001; NS no significance.
Techniques Used: Activity Assay, Bacteria, Flow Cytometry, Staining
Figure Legend Snippet: a E. coli clones in the normal human sera (N. Sera, Quidel), C3deficient sera (C3defi, Quidel), C1 deficient sera (C1 defi, Quidel) and inactive sera at different time points. *C3deficint sera vs normal sera. b E. coli clones in the normal sera (N. Sera, Quidel), CFD-deficient sera (CFD defi, Quidel) inactive sera at different time points. *CFD-deficient sera vs normal sera. c E. coli clones in the normal human sera after adding LPS (containing mannose), mannose or peptidoglycan. *LPS vs normal sera. d E. coli clones in the normal human sera after adding rReg4, rREG4 or mutated rREG4. *Reg4 vs normal sera. Only mrReg4 and only hrREG4, E.coli clones in inactive complement serum after adding mrReg4 or hrREG4. e E. coli clones in the normal human sera after adding different concentrations of rReg4. f E. coli clones in the normal human sera (N. sera) or CFD-deficient (CFD defi) sera after adding rReg4 (N. sera/rReg4 or CFDdefi/rReg4). *Normal sera/Reg4 vs normal sera. g E. coli clones in the normal human sera after adding rREG4, IgA or IgA+REG4. *IgA+Reg4 vs Reg4. Around 5 × 10 5 in a – c or 1 × 10 6 in d – g E. coli CFUs were added into 1 ml 10% sera. Bacterial suspension were diluted and plated on MacConkey agar plates. Plates were incubated overnight at 37 °C, and CFU were counted. Analysis of variance test used in a – g . * P < 0.05; ** P < 0.01; *** P < 0.001; NS no significance. One representative of three independent experiments.
Techniques Used: Clone Assay, Suspension, Incubation
Figure Legend Snippet: a Immunostaining of C3b, C5-9, Reg4, IgA, MASP1/3 and MASP2 on GFP-labeled E. coli in 2% DSS-treated GFP-labeled E. coli infused CFD fl/fl pvillin-cre T (CFDKO/0160) mice (Left) and statistic analyses (right, three images/slide, three slides/mouse, n = 6). Scale bar, 40 μM. No, number; Iso, isotypic antibod. b Flow cytometry of Reg4, IgA, MASP1/3 and MASP2 on the GFP-labeled E. coli in untreated GFP-labeled E. coli infused CFD fl/fl pvillin-cre w (WT) and CFD fl/fl pvillin-cre T (CFDKO) mice and statistic analyses ( n = 3). c ELISA for detecting binding of Reg4 with LPS (left), Reg4 with IgA (middle) or IgA with LPS (right) in different concentration of Reg4 (left and middle) or IgA (right) coated plates d ELISA of C3 in different concentration of Reg4 (left) or IgA (right) with LPS coated plates. For complement resources, 5% normal human sera were added. e ELISA of C3b in the LPS, Reg4, IgA, LPS + Reg4 (LPS/Reg4), LPS + IgA (LPS/IgA), Reg4+IgA (Reg4/IgA) and LPS + Reg4+IgA (LPS/Reg4/IgA) coated plates. For complement resources, 5% normal human sera were added. Mann–Whitney U test in a ; Two side student’s t test in b ; ANOVA plus post-Bonferroni analysis in e ; Analysis of variance test in c and d . * P < 0.05; ** P < 0.01; *** P < 0.001; NS no significance. In c – e , one representative of three independent experiments.
Techniques Used: Immunostaining, Labeling, Flow Cytometry, Enzyme-linked Immunosorbent Assay, Binding Assay, Concentration Assay, MANN-WHITNEY
Related Articles
CDC Assay:Article Title: Methods of treatment or prevention of immune responses and inflammatory diseases with antagonistic CD40 monoclonal antibodies Article Snippet: .. Twenty-five microliters of Incubation:Article Title: Compositions and methods related to engineered Fc constructs Article Snippet: Female C57BL/6 mice weighing 18-22 grams were purchased from Charles River Labs and used in the studies after one week of acclimation. .. other:Article Title: Antagonistic CD40 monoclonal antibodies and uses thereof Article Snippet: Luminescence data was then acquired with a PerkinElmer EnVision® Plate Reader (PerkinElmer, Waltham, MA). Binding Assay:Article Title: Comparative Preclinical Evaluation of Tuznue Versus Referent Herceptin: A Registered Trastuzumab Biosimilar. Article Snippet: .. The binding affinity of Tuznue®, US-based Herceptin® (USHerceptin®), or EU-based Herceptin® (EU-Herceptin®) to Enzyme-linked Immunosorbent Assay:Article Title: Comparative Preclinical Evaluation of Tuznue Versus Referent Herceptin: A Registered Trastuzumab Biosimilar. Article Snippet: .. The binding affinity of Tuznue®, US-based Herceptin® (USHerceptin®), or EU-based Herceptin® (EU-Herceptin®) to |
